# Bevacizumab Plus Ixabepilone to Treat Patients With Advanced Kidney Cancer

> **NCT00923130** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 30 (actual)

## Conditions studied

- Renal Cell Carcinoma

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** Ixabepilone

## Key facts

- **NCT ID:** NCT00923130
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-01-07
- **Primary completion:** 2016-03-01
- **Final completion:** 2016-06
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2018-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00923130

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00923130, "Bevacizumab Plus Ixabepilone to Treat Patients With Advanced Kidney Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00923130. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*